A novel ribosomal protein S6 kinase 2 inhibitor attenuates the malignant phenotype of cutaneous malignant melanoma cells by inducing cell cycle arrest and apoptosis

Malignant melanoma (MM) is a highly life-threatening tumor causing the majority of the cutaneous cancer-related deaths. Previously, ribosomal protein S6 kinase 2 (RSK2), the downstream effector of the MAPK pathway, represents a therapeutic target in melanoma. AE007 is discovered as a targeted RSK2 i...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yayun, Yu, Pian, Long, Jing, Tang, Ling, Zhang, Xu, Zhou, Zhe, Cao, DongSheng, Su, Juan, Chen, Xiang, Peng, Cong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275999/
https://www.ncbi.nlm.nih.gov/pubmed/36700473
http://dx.doi.org/10.1080/21655979.2022.2080364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275999/
https://www.ncbi.nlm.nih.gov/pubmed/36700473
http://dx.doi.org/10.1080/21655979.2022.2080364

Ejemplares similares